glp-1 supply shortage news november 2025 GLP-1s in 2025: Who's Using Them, Who's Covering Them, and What's Next I'm stuck in the gray
Description
Up to date, DS seems to be a rare long-term complication after OAGB and revisional/conversional interventions might not be needed
Start Today
Before you switch, read what experts want you to consider
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lillys Zepbound.
Its a possible effect of the diabetes Rx
Learn about the 72-hour rule, how to safely shift your injection day, and tips to manage potential side effects.
